Small molecule · developed by Viatris Innovation GmbH
Cenerimod (ACT-334441) is an oral drug studied in systemic lupus erythematosus, including lupus nephritis, and in healthy subjects.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT07201129 | Phase 3 | Nephritis, Lupus | Recruiting | VTRS |
| NCT07266090 | Phase 2 | SLE - Systemic Lupus Erythematosus | Active not recruiting | VTRS |
| NCT03742037 | Phase 2 | Systemic Lupus Erythematosus | Completed | VTRS |
| NCT07301723 | Phase 1 | Healthy Subjects | Completed | VTRS |
| NCT02479204 | Phase 1 | Healthy Subjects | Terminated | VTRS |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Lupus Erythematosus, SystemicNephritis, LupusSLE - Systemic Lupus ErythematosusHealthy SubjectsSystemic Lupus Erythematosus
Updated Nov 1, 2026. Something wrong or missing? Report it on the VTRS page.
See VTRS's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
VTRS catalysts and pipeline →